Biological therapy in inflammatory bowel diseases

Access in Central and Eastern Europe

Fanni Rencz, Márta Péntek, Martin Bortlik, Edyta Zagorowicz, Tibor Hlavaty, Andrzej ͆liwczyński, Mihai M. Diculescu, Limas Kupcinskas, Krisztina B. Gecse, L. Gulácsi, P. Lakatos

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Biological drugs opened up new horizons in the management of inflammatory bowel diseases (IBD). This study focuses on access to biological therapy in IBD patients across 9 selected Central and Eastern European (CEE) countries, namely Bulgaria, the Czech Republic, Estonia, Hungary, Latvia, Lithuania, Poland, Romania and Slovakia. Literature data on the epidemiology and disease burden of IBD in CEE countries was systematically reviewed. Moreover, we provide an estimation on prevalence of IBD as well as biological treatment rates. In all countries with the exception of Romania, lower biological treatment rates were observed in ulcerative colitis (UC) compared to Crohn's disease despite the higher prevalence of UC. Great heterogeneity (up to 96-fold) was found in access to biologicals across the CEE countries. Poland, Bulgaria, Romania and the Baltic States are lagging behind Hungary, Slovakia and the Czech Republic in their access to biologicals. Variations of reimbursement policy may be one of the factors explaining the differences to a certain extent in Bulgaria, Latvia, Lithuania, and Poland, but association with other possible determinants (differences in prevalence and incidence, price of biologicals, total expenditure on health, geographical access, and cost-effectiveness results) was not proven. We assume, nevertheless, that health deterioration linked to IBD might be valued differently against other systemic inflammatory conditions in distinct countries and which may contribute to the immense diversity in the utilization of biological drugs for IBD. In conclusion, access to biologicals varies widely among CEE countries and this difference cannot be explained by epidemiological factors, drug prices or total health expenditure. Changes in reimbursement policy could contribute to better access to biologicals in some countries.

Original languageEnglish
Pages (from-to)1728-1737
Number of pages10
JournalWorld Journal of Gastroenterology
Volume21
Issue number6
DOIs
Publication statusPublished - Feb 14 2015

Fingerprint

Eastern Europe
Biological Therapy
Inflammatory Bowel Diseases
Bulgaria
Romania
Poland
Latvia
Lithuania
Slovakia
Hungary
Czech Republic
Health Expenditures
Ulcerative Colitis
Baltic States
Estonia
Drug Utilization
Crohn Disease
Pharmaceutical Preparations
Cost-Benefit Analysis
Epidemiology

Keywords

  • Access
  • Biological therapy
  • Crohn's disease
  • Europe, Central and Eastern
  • Inflammatory bowel diseases
  • Ulcerative colitis

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Biological therapy in inflammatory bowel diseases : Access in Central and Eastern Europe. / Rencz, Fanni; Péntek, Márta; Bortlik, Martin; Zagorowicz, Edyta; Hlavaty, Tibor; ͆liwczyński, Andrzej; Diculescu, Mihai M.; Kupcinskas, Limas; Gecse, Krisztina B.; Gulácsi, L.; Lakatos, P.

In: World Journal of Gastroenterology, Vol. 21, No. 6, 14.02.2015, p. 1728-1737.

Research output: Contribution to journalArticle

Rencz, F, Péntek, M, Bortlik, M, Zagorowicz, E, Hlavaty, T, ͆liwczyński, A, Diculescu, MM, Kupcinskas, L, Gecse, KB, Gulácsi, L & Lakatos, P 2015, 'Biological therapy in inflammatory bowel diseases: Access in Central and Eastern Europe', World Journal of Gastroenterology, vol. 21, no. 6, pp. 1728-1737. https://doi.org/10.3748/wjg.v21.i6.1728
Rencz F, Péntek M, Bortlik M, Zagorowicz E, Hlavaty T, ͆liwczyński A et al. Biological therapy in inflammatory bowel diseases: Access in Central and Eastern Europe. World Journal of Gastroenterology. 2015 Feb 14;21(6):1728-1737. https://doi.org/10.3748/wjg.v21.i6.1728
Rencz, Fanni ; Péntek, Márta ; Bortlik, Martin ; Zagorowicz, Edyta ; Hlavaty, Tibor ; ͆liwczyński, Andrzej ; Diculescu, Mihai M. ; Kupcinskas, Limas ; Gecse, Krisztina B. ; Gulácsi, L. ; Lakatos, P. / Biological therapy in inflammatory bowel diseases : Access in Central and Eastern Europe. In: World Journal of Gastroenterology. 2015 ; Vol. 21, No. 6. pp. 1728-1737.
@article{c0a2a5a9a785425588a41fac1e4023cb,
title = "Biological therapy in inflammatory bowel diseases: Access in Central and Eastern Europe",
abstract = "Biological drugs opened up new horizons in the management of inflammatory bowel diseases (IBD). This study focuses on access to biological therapy in IBD patients across 9 selected Central and Eastern European (CEE) countries, namely Bulgaria, the Czech Republic, Estonia, Hungary, Latvia, Lithuania, Poland, Romania and Slovakia. Literature data on the epidemiology and disease burden of IBD in CEE countries was systematically reviewed. Moreover, we provide an estimation on prevalence of IBD as well as biological treatment rates. In all countries with the exception of Romania, lower biological treatment rates were observed in ulcerative colitis (UC) compared to Crohn's disease despite the higher prevalence of UC. Great heterogeneity (up to 96-fold) was found in access to biologicals across the CEE countries. Poland, Bulgaria, Romania and the Baltic States are lagging behind Hungary, Slovakia and the Czech Republic in their access to biologicals. Variations of reimbursement policy may be one of the factors explaining the differences to a certain extent in Bulgaria, Latvia, Lithuania, and Poland, but association with other possible determinants (differences in prevalence and incidence, price of biologicals, total expenditure on health, geographical access, and cost-effectiveness results) was not proven. We assume, nevertheless, that health deterioration linked to IBD might be valued differently against other systemic inflammatory conditions in distinct countries and which may contribute to the immense diversity in the utilization of biological drugs for IBD. In conclusion, access to biologicals varies widely among CEE countries and this difference cannot be explained by epidemiological factors, drug prices or total health expenditure. Changes in reimbursement policy could contribute to better access to biologicals in some countries.",
keywords = "Access, Biological therapy, Crohn's disease, Europe, Central and Eastern, Inflammatory bowel diseases, Ulcerative colitis",
author = "Fanni Rencz and M{\'a}rta P{\'e}ntek and Martin Bortlik and Edyta Zagorowicz and Tibor Hlavaty and Andrzej ͆liwczyński and Diculescu, {Mihai M.} and Limas Kupcinskas and Gecse, {Krisztina B.} and L. Gul{\'a}csi and P. Lakatos",
year = "2015",
month = "2",
day = "14",
doi = "10.3748/wjg.v21.i6.1728",
language = "English",
volume = "21",
pages = "1728--1737",
journal = "World Journal of Gastroenterology",
issn = "1007-9327",
publisher = "WJG Press",
number = "6",

}

TY - JOUR

T1 - Biological therapy in inflammatory bowel diseases

T2 - Access in Central and Eastern Europe

AU - Rencz, Fanni

AU - Péntek, Márta

AU - Bortlik, Martin

AU - Zagorowicz, Edyta

AU - Hlavaty, Tibor

AU - ͆liwczyński, Andrzej

AU - Diculescu, Mihai M.

AU - Kupcinskas, Limas

AU - Gecse, Krisztina B.

AU - Gulácsi, L.

AU - Lakatos, P.

PY - 2015/2/14

Y1 - 2015/2/14

N2 - Biological drugs opened up new horizons in the management of inflammatory bowel diseases (IBD). This study focuses on access to biological therapy in IBD patients across 9 selected Central and Eastern European (CEE) countries, namely Bulgaria, the Czech Republic, Estonia, Hungary, Latvia, Lithuania, Poland, Romania and Slovakia. Literature data on the epidemiology and disease burden of IBD in CEE countries was systematically reviewed. Moreover, we provide an estimation on prevalence of IBD as well as biological treatment rates. In all countries with the exception of Romania, lower biological treatment rates were observed in ulcerative colitis (UC) compared to Crohn's disease despite the higher prevalence of UC. Great heterogeneity (up to 96-fold) was found in access to biologicals across the CEE countries. Poland, Bulgaria, Romania and the Baltic States are lagging behind Hungary, Slovakia and the Czech Republic in their access to biologicals. Variations of reimbursement policy may be one of the factors explaining the differences to a certain extent in Bulgaria, Latvia, Lithuania, and Poland, but association with other possible determinants (differences in prevalence and incidence, price of biologicals, total expenditure on health, geographical access, and cost-effectiveness results) was not proven. We assume, nevertheless, that health deterioration linked to IBD might be valued differently against other systemic inflammatory conditions in distinct countries and which may contribute to the immense diversity in the utilization of biological drugs for IBD. In conclusion, access to biologicals varies widely among CEE countries and this difference cannot be explained by epidemiological factors, drug prices or total health expenditure. Changes in reimbursement policy could contribute to better access to biologicals in some countries.

AB - Biological drugs opened up new horizons in the management of inflammatory bowel diseases (IBD). This study focuses on access to biological therapy in IBD patients across 9 selected Central and Eastern European (CEE) countries, namely Bulgaria, the Czech Republic, Estonia, Hungary, Latvia, Lithuania, Poland, Romania and Slovakia. Literature data on the epidemiology and disease burden of IBD in CEE countries was systematically reviewed. Moreover, we provide an estimation on prevalence of IBD as well as biological treatment rates. In all countries with the exception of Romania, lower biological treatment rates were observed in ulcerative colitis (UC) compared to Crohn's disease despite the higher prevalence of UC. Great heterogeneity (up to 96-fold) was found in access to biologicals across the CEE countries. Poland, Bulgaria, Romania and the Baltic States are lagging behind Hungary, Slovakia and the Czech Republic in their access to biologicals. Variations of reimbursement policy may be one of the factors explaining the differences to a certain extent in Bulgaria, Latvia, Lithuania, and Poland, but association with other possible determinants (differences in prevalence and incidence, price of biologicals, total expenditure on health, geographical access, and cost-effectiveness results) was not proven. We assume, nevertheless, that health deterioration linked to IBD might be valued differently against other systemic inflammatory conditions in distinct countries and which may contribute to the immense diversity in the utilization of biological drugs for IBD. In conclusion, access to biologicals varies widely among CEE countries and this difference cannot be explained by epidemiological factors, drug prices or total health expenditure. Changes in reimbursement policy could contribute to better access to biologicals in some countries.

KW - Access

KW - Biological therapy

KW - Crohn's disease

KW - Europe, Central and Eastern

KW - Inflammatory bowel diseases

KW - Ulcerative colitis

UR - http://www.scopus.com/inward/record.url?scp=84922747685&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84922747685&partnerID=8YFLogxK

U2 - 10.3748/wjg.v21.i6.1728

DO - 10.3748/wjg.v21.i6.1728

M3 - Article

VL - 21

SP - 1728

EP - 1737

JO - World Journal of Gastroenterology

JF - World Journal of Gastroenterology

SN - 1007-9327

IS - 6

ER -